A carregar...
Angiotensin II for the treatment of septic shock in a neutropenic patient with T-cell acute lymphoblastic leukaemia
Mortality remains high in septic shock with few new treatment options. Angiotensin II has been recently approved for use in septic shock due to promising results in the ATHOS-3 trial. However, patients with neutropenia were excluded in the trial. This patient population is becoming increasingly comm...
Na minha lista:
| Publicado no: | BMJ Case Rep |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7322323/ https://ncbi.nlm.nih.gov/pubmed/32595128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-233432 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|